Long Focus Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Long Focus Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$251K	–	122
2022 Q3	$251K	Sell	10,000 -13,000	-57%	-$360K	0.02%	93
2022 Q2	$699K	Hold	23,000	–	–	0.07%	84
2022 Q1	$753K	Sell	23,000 -25,000	-52%	-$742K	0.1%	82
2021 Q4	$1.27M	Buy	+48,000	New	+$3.71M	0.17%	66

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Long Focus Capital Management's RETA Position: Q4 2022 in Review

Long Focus Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 10,000 shares — an estimated $251K sold.

Long Focus Capital Management first reported a position in RETA in Q4 2021 and held it in 4 quarters. The position peaked at $1.27M in Q4 2021. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

Long Focus Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Long Focus Capital Management sold 10,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $251K.
Long Focus Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2021 and held it in 4 quarters.
Long Focus Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.27M in Q4 2021.
168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Long Focus Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.